This trial will test whether nivolumab can prevent recurrence of PCNSL in patients who have completed first-line treatment.
2 Primary · 0 Secondary · Reporting Duration: 12 months
Side Effects for
1 Treatment Group
1 of 1
25 Total Participants · 1 Treatment Group
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 17 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any open recruitment opportunities related to this clinical trial?
"Affirmative. Records hosted on clinicaltrials.gov attest that recruitment for this medical trial is ongoing, with 25 patients needed from seven sites since its posting in May of 2020 and subsequent updates in May 2022." - Anonymous Online Contributor
Is there a precedent for using Nivolumab in medical research?
"Nivolumab was initially studied in 2012 by a Local Institution. Currently, there are 718 active clinical trials, with many of them being hosted out of Middletown, New York; the total number of completed studies is 252." - Anonymous Online Contributor
How many participants are there in this clinical experiment?
"Affirmative, the information found on clinicaltrials.gov indicates that this research is now recruiting participants. First posted on May 22nd 2020 and last edited on May 6th 2022, the study plans to recruit 25 individuals from 7 trial sites." - Anonymous Online Contributor
How many geographic sites are currently administering this clinical trial?
"Currently, seven sites are recruiting patients for this clinical trial. These include Memorial Sloan Kettering Monmouth (Limited Protocol Activities) in Middletown, Memorial Sloan Kettering Bergen (Limited Protocol Activities) in Montvale and Memorial Sloan Kettering Commack (Limited Protocol Activities), with an additional four centres involved." - Anonymous Online Contributor
Is this an unprecedented clinical trial?
"As of today, Nivolumab is being tested in 718 active clinical trials that span across 49 distinct countries and 2356 cities. The initial exploration into this medication began back in 2012 with Ono Pharmaceutical Co. Ltd sponsoring a study involving 659 patients; since then, 252 studies have been successfully concluded." - Anonymous Online Contributor
Could you elucidate the safety profile of Nivolumab?
"The safety of Nivolumab was rated two due to the Phase 2 status, suggesting that there is some evidence for its security but not yet any proof regarding efficacy." - Anonymous Online Contributor
To what medical conditions is Nivolumab typically prescribed?
"Nivolumab is most commonly used to treat cancerous tumours. However, it has also been successful in treating other ailments such as unresectable melanoma and metastatic esophageal adenocarcinoma." - Anonymous Online Contributor